Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia (PEG-rhG-CSF)
Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Listed as NCT01918241, this PHASE2 trial focuses on Neutropenia and remains ongoing. Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Nov 2022 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Changsha Central Hospital
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Jiangsu Cancer Institute & Hospital
- Peking University Cancer Hospital & Institute
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Shandong Cancer Hospital and Institute
- Subei People's Hospital of Jiangsu Province
- The Affiliated Hospital of Inner Mongolia Medical University
- The First Affiliated Hospital with Nanjing Medical University
- Wuhan TongJi Hospital
- Yangzhou No.1 People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .